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Abstract
Background:  Mutations in GJB2  are the most common molecular defects responsible for
autosomal recessive nonsyndromic hearing impairment (NSHI). The mutation spectra of this gene
vary among different ethnic groups.
Methods: In order to understand the spectrum and frequency of GJB2 mutations in the Chinese
population, the coding region of the GJB2 gene from 2063 unrelated patients with NSHI was PCR
amplified and sequenced.
Results: A total of 23 pathogenic mutations were identified. Among them, five (p.W3X, c.99delT,
c.155_c.158delTCTG, c.512_c.513insAACG, and p.Y152X) are novel. Three hundred and seven
patients carry two confirmed pathogenic mutations, including 178 homozygotes and 129 compound
heterozygotes. One hundred twenty five patients carry only one mutant allele. Thus, GJB2
mutations account for 17.9% of the mutant alleles in 2063 NSHI patients. Overall, 92.6% (684/739)
of the pathogenic mutations are frame-shift truncation or nonsense mutations. The four prevalent
mutations; c.235delC, c.299_c.300delAT, c.176_c.191del16, and c.35delG, account for 88.0% of all
mutantalleles identified. The frequency of GJB2 mutations (alleles) varies from 4% to 30.4% among
different regions of China. It also varies among different sub-ethnic groups.
Conclusion: In some regions of China, testing of the three most common mutations can identify
at least one GJB2 mutant allele in all patients. In other regions such as Tibet, the three most
common mutations account for only 16% the GJB2 mutant alleles. Thus, in this region, sequencing
of GJB2 would be recommended. In addition, the etiology of more than 80% of the mutant alleles
for NSHI in China remains to be identified. Analysis of other NSHI related genes will be necessary.
Introduction
Hearing impairment is the most common neurosensory
disorder in humans. The reported incidence varies from 1
in 300 to 1 in 1000 children [1-4]. Approximately half of
cases have a genetic etiology, including syndromic and
non-syndromic forms, with extraordinary genetic hetero-
geneity. Non-syndromic deafness accounts for 60–70% of
inherited hearing impairment. It involves more than 100
different genes with autosomal dominant (DFNA), auto-
somal recessive (DFNB), X-linked (DFN), and maternal
inheritance [5], with autosomal recessive being the most
common. For many populations, the most common cause
for non-syndromic autosomal recessive hearing loss is
mutated Connexin 26, a gap junction protein encoded by
the GJB2 gene (MIM 121011) [6-13]. There are a few spe-
cific mutations in GJB2 gene that are associated with the
autosomal dominant syndromic forms of deafness, and
typically present with skin abnormalities including kerati-
tis-ichthyosis [14-16].
Connexins are transmembrane proteins. Six monomers of
connexin proteins associate to form a transmembrane
hexameric gap junction hemi-channel called a connexon.
Connexons embedded in the surfaces of adjacent cells
associate to form an intercellular channel [17,18]. In the
inner ear, connexin 26 can be in association with other
connexins to form heteromeric connexons. Gap junction
channels can be homotypic or heterotypic. Connexin 26
gap junction channels recycle potassium ions as part of a
mechanism of auditory signal transduction in inner ear
[19].
Mutations in three connexin (Cx) genes, GJB2  (Cx26),
GJB6 (Cx30), and GJB3 (Cx31), have been identified and
are known to cause hearing impairment [18,19].
Sequence analysis of the GJB2 gene in subjects with auto-
somal recessive hearing impairment revealed that a high
number of patients carried only one mutant allele. Some
of these families showed clear evidence of linkage to the
DFNB1 locus, which contains two genes, GJB2 and GJB6
[6,20]. Further analysis demonstrated that some GJB2 het-
erozygotes also carried a truncating deletion of the GJB6
gene, encoding connexin 30, in trans [21,22].
To date, more than 150 mutations, polymorphisms, and
unclassified variants have been described in the GJB2 gene
http://davinci.crg.es/deafness. The mutation spectrum
and prevalence of mutations vary significantly among dif-
ferent ethnic groups. Three mutations, c.35delG,
c.167delT, and c.235delC, are found to be the most fre-
quent mutations in Caucasian, Ashkenazi Jewish, and
Asian populations, respectively [6,7,9-13,20,23-26].
In China, it is estimated that 30,000 babies are born with
congenital hearing impairment every year [27]. The muta-
tion spectrum of the GJB2 gene in Chinese patients with
nonsyndromic hearing impairment (NSHI) has not been
analyzed. Our recent study by screening for just the mostJournal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
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common mutation, c.235delC, in 3004 Chinese NSHI
patients revealed that 488 (16.3%) patients carried at least
one c.235delC mutant allele, with 233 (7.8%) homozy-
gotes and 255 (8.5%) heterozygotes [28], though the fre-
quencies of homozygote and heterozygote of c.235delC
varied from 0% to 14.7% and from 1.7% to 16.1% respec-
tively in the populations examined in this study. Among
different Chinese sub-ethnic groups the c.235delC allele
frequency was the lowest (0.8%) in the Tibetan and the
highest (31.0%) in Maan. These results highlight the need
to sequence the entire GJB2 gene in order to more accu-
rately establish the actual mutation frequency and muta-
tion spectrum of GJB2 gene within various Chinese sub-
populations. Our preliminary results reveal that other
GJB2 mutations account for an additional 7.1% of NSHI
patients from Qinghai, where only 7.1% patients carried
at least one c.235delC mutation. Nevertheless, sequenc-
ing analysis of the entire coding region of the GJB2 gene
in patients from Guangxi where the frequency of the
c.235delC mutation is 3.4% reveals only one other muta-
tion in 87 deaf patients. These results have two important
implications: that the GJB2 gene needs to be sequenced in
its entirety; and that mutations in genes responsible for
NSHI other than GJB2 should be searched in patients who
do not harbor two mutant alleles in the GJB2 gene. In this
study, we report the results of sequencing the GJB2 gene
in 2063 patients with NSHI from 23 different regions of
China (Figure 1).
Materials and methods
Patients and DNA samples
A total of 2063 unrelated NSHI students from 23 different
regions of China were included in this sequencing study.
The selection of samples was random regardless of the
c.235delC genotype. The patients consisted of 1179 males
and 884 females ranging in age from 2 to 30 years with an
average age of 13.7 ± 4.5. The majority of patients were
Han Chinese (1640), followed by Tibetan (122), minori-
ties in the Southwest region (119), Hui (79), minorities in
Xinjiang (62), Mongolian (21), Maan (18) and Korean
(2). Ethnic subgroup designations were based on perma-
nent residency documentation.
This study was performed according to a protocol
approved by the ethics committee of the Chinese PLA
General Hospital. The subjects in this study were from
deaf schools of each region and were recently described
[28]. Only the unrelated patients with nonsyndromic
hearing loss were included in this study. Parents were not
included in this study. All patients showed moderate to
profound bilateral sensorineural hearing impairment on
audiograms and no pathient with mild hearing impair-
ment was found in this cohort. In addition to the 2063
patients, 301 Han control individuals with normal hear-
ing (either evaluated by pure tone audiometry or by self-
assessment) from Beijing Capital (Northern) and Jiangsu
Province (Eastern), two densely populated regions con-
sisting of 98% Han Chinese, were also analyzed. DNA was
extracted from peripheral blood leukocytes using a com-
mercially available DNA extraction kit (Watson Biotech-
nologies Inc, Shanghai, China).
Sequence analysis
The coding exon (Exon2) and flanking intronic regions of
GJB2  gene were PCR amplified with forward primer
5'TTGGTGTTTGCTCAGGAAGA 3' and reverse primer
5'GGCCTACAGGGGTTTCAAAT 3'. Among this study
cohort, 851 patients from central China were also ana-
lyzed for mutations in Exon1 and flanking introns by
PCR/sequencing. The PCR primers used are forward
primer:
5'CTCATGGGGGCTCAAAGGAACTAGGAGATCGG3'
and reverse primer 5'GGGGCTGGACCAACACACGTC-
CTT GGG3'. The PCR products were purified on Qia-quick
spin columns (Qiagen, Valencia, CA) and sequenced
using the BigDye Terminator Cycle Sequencing kit (ver-
sion v3.1) and ABI 3130 automated DNA sequencers
(Applied Biosystems, Foster City, CA, USA,) with
Sequence Analysis Software (Sequencing Analysis version
3.7). DNA sequence variations were identified by compar-
ison of subject DNA sequence to GJB2  reference
sequences, Genebank Accession Number AY280971.
Numbering of GJB2 begins with the nucleotide A of the
ATG start codon in Exon2 as cDNA position number 1.
Geographic distribution and the proportion of patients carry- ing at least one GJB2 mutant allele in each region studied Figure 1
Geographic distribution and the proportion of 
patients carrying at least one GJB2 mutant allele in 
each region studied.Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
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The sequences were analyzed using Genetool Lite software
and the GJB2 Genebank sequence. The presence of 309 kb
deletion of GJB6 was analyzed by PCR method [21,22]. A
positive control of this deletion provided by Balin Wu
(Department of Laboratory Medicine, Children's Hospital
and Harvard Medical School, USA.) was used for the
detection of deletion in GJB6 gene.
Statistical analysis
The statistical analysis was performed using SAS 9.1.3
software (SAS, Cary, North Carolina, USA).
Results
Mutations in GJB2 gene
Sequencing of the coding region of the GJB2 gene revealed
that at least 104 different genotypes were found in the
2063 patients (Table 1). Among them, 64 different geno-
types harboring pathogenic mutations were found in 432
patients (Table 1). Three hundred and seven patients had
two confirmed pathogenic mutations, including 178
homozygotes and 129 compound heterozygotes. One
hundred twenty five patients carried one heterozygous
pathogenic mutation without an identified second
mutant allele. Thus, GJB2  mutant alleles account for
17.9% (739/4126) of the total alleles in 2063 NSHI
patients. The most common genotype was homozygous
c.235delC, followed by compound heterozygosity for
c.235delC/c.299_300delAT, which accounted for 8.0%
(164/2063) and 3.2% (66/2063) of NSHI patients respec-
tively. The most common mutation c.235delC was in
compound heterozygosity with 14 other different patho-
genic mutations in 113 patients, and was present as a sin-
gle heterozygous mutant allele in 68 patients. In addition,
there were 23 different genotypes in patients carrying one
allele of unclassified variants (Table 1). Twenty-three
alterations were found, five (p.W3X, c.99delT,
c.155_c.158delTCTG, p.Y152X, and
c.512_c.513insAACG) of them were novel and patho-
genic, and twelve (p,G21R, p,I30F, p.F31L, p.V37I,
p.V63L, p.T123N, p.V153A, p.D159N, p.F191L, p.M195V,
p.V198M, and p.I215N) are unclassified variants (Table 1
and Supplemental Table 1). The distribution of various
genotypes in 23 regions (Figure 1) is detailed in Table 2
and Supplemental Table 2. The frequencies of the three
most common GJB2 mutations in the 23 regions studied
are listed in Table 2. The allele frequency of all mutations
in the GJB2 gene in NSHI patients varied from 4.0% in
Guangxi to 30.4% in Jiangsu (Table 2). Regions which
appeared to have a higher frequency of the c.235delC
mutation (Jiangsu, Inner Mongolia, Beijing, Hebei,
Shanghai) also had a relatively high frequency of other
GJB2 mutations (eg, the frequency of the c.235delC muta-
tion in Jiangsu was as high as 20.6% and the frequencies
of other mutations were also as high as 9.8%). Similarly,
regions such as Shaanxi and Guangxi where the frequency
of the c.235delC mutation is low (5.8 and 3.4% respec-
tively), also had lower frequencies of other mutations (1.9
and 0.6% respectively). Patients from Tibet, Yunnan, Xin-
jiang, Heilongjiang, and Ningxia appear to have the most
diverse mutation spectrum because uncommon muta-
tions (except c.235delC, c.299_c.300delAT and
c.176_c.191del16) comprise 84.2, 30.8, 26.1, 21.4, and
20.4%, respectively of overall GJB2 mutations in those
regions.
Frame-shift and nonsense Pathogenic Mutations
The c.235delC is the most prevalent mutation in the Chi-
nese NSHI population with a total of 509 alleles (164
homozygous, 113 compound heterozygous with other
pathogenic mutant alleles, and 68 one heterozygous allele
only), followed by 98 c.299_c.300delAT mutant alleles (8
homozygotes, 76 compound heterozygotes, and 6 one
allele heterozygotes), 31 c.176_c.191del16 mutant alleles
(2 homozygous, 25 compound heterozygous and 2 with
only one allele), and 12 c.35delG mutant alleles(2
homozygous, 3 compound heterozygous and 2 with only
one allele) (Supplemental Table 1). The four prevalent
mutations account for 88.0% (650/739) of all mutant
alleles identified. Five novel mutations were identified in
20 patients; including two nonsense; p.W3X, p.Y152X,
and 4 frame-shift truncation mutations; c.99delT, c.155–
c.158 delTCTG, and c.512–c.513 insAACG. Among these,
c.512–c.513insAACG occurs in 12 patients, including one
homozygous from Yunnan. The novel truncation muta-
tions account for only about 3.1% (23/739, Supplemental
Table 1) of the overall GJB2 mutant alleles. The most prev-
alent Caucasian mutation, c.35delG, was found in 2
homozygous, 3 compound heterozygous, and 5 single
allele heterozygous patients. Among the patients with
c.35delG, 70% of patients (7/10) are Uigur from Xinjiang
area. The c.35insG mutation was found in 2 patients
(both are Hui people) compound heterozygous with the
c.235delC mutation. Other reported frame-shift muta-
tions; 1 c.388–c.397del10 and 3 c.605–c.606ins46, as
well as nonsense mutations; 3 p.E47X, account for a small
fraction (1.0%) of GJB2 mutant alleles. Overall, 92.6%
(684/739) of the pathogenic mutations are frame-shift
truncation or nonsense mutations, and they are predicted
to cause loss of function of connexin 26. Only 6.9% (51/
739) of the mutant alleles are reported missense muta-
tions.
Reported missense pathogenic mutations
There are 8 reported missense pathogenic mutations and
1 in-frame deletion of 1 single amino acid,
c.424_c.426del3 (p.del142F), which occurs in 4 hetero-
zygous patients (Supplemental Table 1). The 8 missense
mutations are p.G4D (3 heterozygous patients), p.R32C
(one patient in compound heterozygosity with
c.235delC), p.R143W (4 compound heterozygotes),Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
Page 5 of 12
(page number not for citation purposes)
Table 1: GJB2 genotypes of 2063 Chinese NSHI patients
Allele 1 Allele 2
nucleotide change consequence or 
amino acid 
change
category domain nucleotide change consequence or 
amino acid change
Category domain Number of 
patientsd
homozygous
c.35delG frame-shift pathogenic NT c.35delG frame-shift Pathogenic 2
c.176_c.191del16 fram shift pathogenic EC1 c.176_c.191del16 frame-shift Pathogenic EC1 2
c.235delC frame-shift pathogenic TM2 c.235delC frame-shift Pathogenic TM2 164
c.299_c.300delAT frame-shift pathogenic CL c.299_c.300delAT frame-shift pathogenic CL 8
c.512_c.513insAACG frame-shift pathogenic EC2 c.512_c.513insAACG frame-shift pathogenic EC2 1
c.605_c.606ins46 frame-shift pathogenic TM4 c.605_c.606ins46 frame-shift pathogenic TM4 1
compound heterozygous
c.9G>A, c.79G>A p.W3X, p.V27I pathogenic, 
polymophism
NT, TM1 c.427C>T p.R143W pathogenic TM3 1
c.35delG frame-shift pathogenic NT c.299_c.300delAT frame-shift pathogenic CL 1
c.35delG frame-shift pathogenic NT c.313_c.326del14 frame-shift pathogenic CL 1
c.176_c.191del16 frame-shift pathogenic EC1 c.9G>A, c.79G>A p.W3X, p.V27I pathogenic, 
polymophism
NT+TM1 2
c.176_c.191del16 frame-shift pathogenic EC1 c.299_c.300delAT frame-shift pathogenic CL 4
c.176_c.191del16 frame-shift pathogenic EC1 c.388_c.397del10 frame-shift pathogenic 1
c.235delC frame-shift pathogenic TM2 c.9G>A, c.79G>A p.W3X, p.V27I pathogenic, 
polymophism
NT+TM1 2
c.235delC frame-shift pathogenic TM2 c.35delG frame-shift pathogenic NT 1
c.235delC frame-shift pathogenic TM2 c.35insG frame-shift pathogenic NT 2
c.235delC frame-shift pathogenic TM2 c.94C>T p.R32C pathogenic TM1 1
c.235delC frame-shift pathogenic TM2 c.99delT frame-shift pathogenic TM1 1
c.235delC frame-shift pathogenic TM2 c.139G>T p.E47X pathogenic EC1 3
c.235delC frame-shift pathogenic TM2 c.155_c.158delTCTG frame-shift pathogenic EC1 2
c.235delC frame-shift pathogenic TM2 c.176_191del16 frame-shift pathogenic EC1 18
c.235delC frame-shift pathogenic TM2 c.257C>G p.T86R pathogenic TM2 6
c.235delC frame-shift pathogenic TM2 c.299_c.300delAT frame-shift pathogenic CL 65
c.235delC frame-shift pathogenic TM2 c.299_c.300delAT, 
c.79G>A
frame-shift, p.V27I frame-shift, 
polymorphism
CL+TM1 1
c.235delC frame-shift pathogenic TM2 c.313_c.326del14 frame-shift pathogenic CL 1
c.235delC frame-shift pathogenic TM2 c.427C>T p.R143W pathogenic TM3 3
c.235delC frame-shift pathogenic TM2 c.512_c.513insAACG frame-shift pathogenic EC2 6
c.235delC frame-shift pathogenic TM2 c.605_c.606ins46 frame-shift pathogenic TM4 1
c.299_c.300delAT frame-shift pathogenic CL c.139G>A p.E47K pathogenic EC1 1
c.299_c.300delAT frame-shift pathogenic CL c.257C>G p.T86R pathogenic TM2 1
c.299_c.300delAT frame-shift pathogenic CL c.512_c.513insAACG frame-shift pathogenic EC2 3
c.456C>A p.Y152X pathogenic TM3, CL c.380G>A, c.79G>A, 
c.341A>G
p.R127H, p.V27I, 
E114G
pathogenic, 
polymophism
TM1+CL 1
heterozygous (one mutant allele only)
c.11G>A p.G4D pathogenic NT c.109G>A p.V37I see note TM1 1
c.11G>A p.G4D pathogenic NT Nv 2
c.35delG frame-shift pathogenic NT c.79G>A, c.341A>G p.V27I p,E114G polymorphism TM1+CL 1
c.35delG frame-shift pathogenic NT Nv 4
c.155_c.158delTCTG frame-shift pathogenic EC1 c.341A>G, c.644T>A p.E114G, p.I215N polymorphism, 
unclassified
CL+CT 1
c.176_c.191del16 frame-shift pathogenic EC1 Nv 2
c.235delC frame-shift pathogenic TM2 c.109G>A p.V37I see note TM1 11
c.235delC frame-shift pathogenic TM2 c.79G>A p.V27I polymorphism TM1 6
c.235delC frame-shift pathogenic TM2 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 5
c.235delC frame-shift pathogenic TM2 c.341A>G p.E114G polymorphism CL 2
c.235delC frame-shift pathogenic TM2 c.558G>A p.T186T polymorphism EC2 1
c.235delC frame-shift pathogenic TM2 Nv 43
c.253T>C p.S85P pathogenic TM2 Nv 1
c.299_c.300delAT frame-shift pathogenic CL c.109G>A p.V37I see note TM1 1
c.299_c.300delAT frame-shift pathogenic CL c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.299_c.300delAT frame-shift pathogenic CL Nv 4
c.380G>A, c.341A>G p.R127H, 
p.E114G
pathogenic, 
polymophism
CL+CL c.109G>A p.V37I see note TM1 1
c.380G>A p.R127H pathogenic CL c.109G>A p.V37I see note TM1 1
c.380G>A, c.109G>A p.R127H, p.V37I pathogenic, 
polymophism
TM1+CL c.79G>A p.V27I polymorphism TM1 1
c.380G>A, c.79G>A p.R127H, p.V27I pathogenic, 
polymophism
TM1+CL c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.380G>A p.R127H pathogenic CL c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 9
c.380G>A, c.147C>T p.R127H, p.A49A pathogenic, 
polymophism
EC1+CL c.79G>A p.V27I polymorphism TM1 1Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
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c.380G>A, c.608T>C p.R127H, p.I203T pathogenic, 
polymophism
CL+TM4 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.380G>A, c.608T>C p.R127H, p.I203T pathogenic, 
polymophism
CL+TM4 c.79G>A p.V27I polymorphism TM1 1
c.380G>A p.R127H pathogenic CL c.79G>A p.V27I polymorphism TM1 4
c.380G>A p.R127H pathogenic CL c.457G>A p.V153I polymorphism TM3 1
c.380G>A p.R127H pathogenic CL Nv 10
c.416G>A p.S139N pathogenic CL c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.416G>A p.S139N pathogenic CL Nv 1
c.424_c.426del3 p.del142F pathogenic TM3 c.79G>A, c.341A>G, 
c.109G>A
p.V27I, p.E114G, 
p.V37I
polymorphisms, 
see note
TM1+CL 3
c.424_c.426del3 p.del142F pathogenic TM3 c.79G>A, c.109G>A p.V27I, p.V37I polymorphisms, 
see note
TM1 1
c.512_c.513insAACG frame-shift pathogenic EC2 c.79G>A, c.368C>A p.V27I, p.T123N polymorphism, 
unclassified
TM1+CL 1
c.512_c.513insAACG frame-shift pathogenic EC2 Nv 1
unclassified variant
c.61G>C, c.79G>A p.G21R, p.V27I unclassified, 
polymorphism
NT+TM1 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.88A>T p.I30F unclassified TM1 Nv 1
c.93T>G p.F31L unclassified TM1 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.187G>T p.V63L unclassified EC1 Nv 2
c.368C>A, c.79G>A p.T123N, p.V27I unclassified, 
polymorphism
CL+TM1 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.368C>A, c.79G>A p.T123N, p.V27I unclassified, 
polymorphism
CL+TM1 c.79G>A p.V27I polymorphism TM1 3
c.368C>A p.T123N unclassified CL c.79G>A p.V27I polymorphism TM1 7
c.368C>A, c.608T>C p.T123N, p.I203T unclassified, 
polymorphism
CL+TM4 c.79G>A p.V27I polymorphism TM1 1
c.458T>C p.V153A unclassified EC2 c.608T>C p.I203T polymorphism TM4 1
c.571T>C, c.592G>A p.F191L, 
p.V198M
unclassified TM4+TM4 c.79G>A p.V27I polymorphism TM1 1
c.583A>G p.M195V unclassified TM4 Nv 1
c.583A>G p.M195V unclassified TM4 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.592G>A, c.79G>A, 
c.341A>G
p.V198M, p.V27I, 
p.E114G
unclassified, 
polymorphism
TM4+TM1
+CL
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.592G>A, c.79G>A p.V198M, p.V27I unclassified, 
polymorphism
TM4+TM1 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.592G>A p.V198M unclassified TM4 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 2
c.475G>A p.D159N unclassified EC2 Nv TM1+CL 1
c644T>A, c.79G>A, 
c.341A>G
p.I215N, p.V27I, 
p.E114G
unclassified, 
polymorphism
CT+TM1+
CL
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 1
c.644T>A p.I215N unclassified CT c.608T>C p.I203T polymorphism TM4 1
c.109G>A p.V37I see note TM1 c.109G>A p.V37I see note TM1 23
c.109G>A p.V37I see note TM1 c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 29
c.109G>A p.V37I see note TM1 c.79G>A p.V27I polymorphism TM1 10
c.109G>A p.V37I see note TM1 c.608T>C p.I203T polymorphism TM4 3
c.109G>A p.V37I see note TM1 Nv 91
polymorphism
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL 90
c.79G>A p.V27I polymorphism TM1 c.79G>A p.V27I polymorphism TM1 18
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL c.79G>A p.V27I polymorphism TM1 42
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL c.341A>G p.E114G polymorphism 2
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL c.457G>A p.V153I polymorphism TM3 1
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL c.608T>C p.I203T polymorphism TM4 12
c.79G>A, c.341A>G p.V27I, p.E114G polymorphism TM1+CL Nv 387
c.79G>A p.V27I polymorphism TM1 c.608T>C p.I203T polymorphism TM4 5
c.79G>A, c.608T>C p.V27I polymorphism TM1+TM4 c.608T>C p.I203T polymorphism TM4 1
c.79G>A p.V27I polymorphism TM1 Nv 202
c.147C>T p.A49A polymorphism EC1 Nv 1
c.181A>G p.K61K polymorphism EC1 Nv 1
c.341A>G p.E114G polymorphism CL Nv 14
c.438C>T p.F146F polymorphism TM3 Nv 2
c.608T>C p.I203T polymorphism TM4 c.608T>C p.I203T polymorphism TM4 3
c.608T>C p.I203T polymorphism TM4 Nv 28
nv Nv 638
total 2063
nv: no variant
Note: p.V37I is controversy variant, see the discussion.
Table 1: GJB2 genotypes of 2063 Chinese NSHI patients (Continued)J
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Table 2: Prevalence of GJB2 mutations in different areas of China
Number of NSHI c.235delC allele c.299_c.300delAT allele c.176_c.191del16 allele Uncommon mutant allele total 
number 
of mutant 
alleles
(%)
total with two 
mutation
1 allele 
with one 
mutaion
number 
with 1 
mutant 
allele (%)
homo het total (%)a homo het total (%)a homo het total (%)a homo het total (%)a
Jiangsu 102 26 10 36 (35.3) 12 18 42 (67.7) 2 7 11 (17.7) 1 7 9 (14.5) 0 0 0 30.4
Nei Mongol 115 30 5 35 (30.4) 14 18 46 (70.8) 0 11 11 (16.9) 0 3 3 (4.6) 1 3 5 (7.7) 28.3
Beijing 155 37 6 43 (27.7) 24 13 61 (76.3) 0 10 10 (12.5) 0 0 0 0 9 9 (11.3) 25.8
Hebei 64 14 3 17 (26.6) 7 9 23 (74.2) 0 3 3 (9.7) 0 1 1 (3.2) 0 4 4 (12.9) 24.2
Shanghai 31 7 1 8 (25.8) 3 5 11 (73.3) 0 2 2 (13.3) 0 1 1 (6.7) 0 1 1 (6.7) 24.2
Heilongjiang 36 5 4 9 (25.0) 1 7 9 (64.3) 0 2 2 (14.3) 0 0 0 0 3 3 (21.4) 19.4
Guangdong 77 15 4 19 (24.7) 10 7 27 (79.4) 0 4 4 (11.8) 0 0 0 0 3 3 (8.8) 22.1
Sichuan 109 17 8 25 (22.9) 10 13 33 (78.6) 0 3 3 (7.1) 0 4 4 (9.5) 0 2 2 (4.8) 19.3
Shanxi 57 11 2 13 (22.8) 4 9 17 (70.8) 0 5 5 (20.8) 0 1 1 (4.2) 0 1 1 (4.2) 21.1
Gansu 42 7 2 9 (21.4) 3 5 11 (68.8) 0 3 3 (18.8) 0 0 0 0 2 2 (12.5) 19
Jilin 57 12 0 12 (21.1) 7 4 18 (75.0) 0 5 5 (21.0) 0 0 0 0 1 1 (4.0) 21.1
Fujian 48 6 4 10 (20.8) 5 4 14 (87.5) 0 1 1 (6.3) 0 0 0 0 1 1 (6.3) 16.7
Ningxia 145 20 9 29 (20.0) 8 14 30 (61.2) 1 3 5 (10.2) 0 4 4 (8.2) 0 10 10 (20.4) 16.9
Xinjiang 136 19 8 27 (19.9) 9 5 23 (50.0) 2 4 8 (17.4) 0 3 3 (6.5) 1 10 12 (26.1) 16.9
Hubei 47 7 2 9 (19.1) 6 2 14 (87.5) 0 0 0 0 0 0 0 2 2 (12.5) 17
Yunnan 230 23 19 42 (18.3) 11 14 36 (55.4) 1 3 5 (7.7) 1 2 4 (6.2) 1 18 20 (30.8) 14.1
Guiyang 138 23 2 25 (18.1) 16 9 41 (85.4) 0 6 6 (12.5) 0 0 0 0 1 1 (2.1) 17.4
Henan 126 16 5 21 (16.7) 10 8 28 (75.7) 0 5 5 (13.5) 0 0 0 0 4 4 (10.8) 14.7
Tibet 118 0 19 19 (16.1) 0 2 2 (10.5) 0 1 1 (5.3) 0 0 0 0 16 16 (84.2) 8.1
Qinghai 56 5 3 8 (14.3) 1 3 5 (38.5) 2 2 6 (46.2) 0 0 0 0 2 2 (15.4) 11.6
Anhui 35 3 2 5 (14.3) 1 4 6 (75.0) 0 1 1 (12.5) 0 1 1 (12.5) 0 0 0 11.4
Shaanxi 52 3 2 5 (9.6) 1 4 6 (75.0) 0 1 1 (12.5) 0 0 0 0 1 1 (12.5) 7.7
Guangxi 87 1 5 6 (6.9) 1 4 6 (85.7) 0 0 0 0 0 0 0 1 1 (14.3) 4
total 2063 307 125 432 164 181 345 8 82 90 2 27 29 3 95 98 17.9
homo: homozygous; het: hetrozygous; apercentage of total mutant alleles identified.Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
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p.T86R (all compound heterozygous, 6 with c.235delC
and 1 with c.299_c.300delAT), p.R127H (one compound
with p.Y152X, 31 single heterozygotes), p.S139N (2 single
heterozygotes), p.E47K (one compound with
c.299_c.300delAT), p.S85P (single heterozygote). All
occur in an evolutionarily highly conserved region (Figure
2) [26,29,30].
Unclassified Variants
Twelve unclassified missense variants were identified. The
p.G21R is most likely to be pathogenic based on its highly
evolutionarily conserved nature and the dramatic effect of
the amino acid substitutions on structure and ionic
strength. The p.I215N variant is located in the conserved
region of C-terminal ion channel domain. Replacing the
hydrophobic amino acid isoleucine with a hydrophilic
amino acid asparagine in this conserved region is expected
to cause detrimental effect. This variant is also in com-
pound heterozygous with a novel pathogenic mutation,
c.155_c.158delTCTG. Thus, it is likely to be pathogenic.
The missense variants, p.I30F, p.F31L, p.V63L, p.V153A,
p.D159N, p.F191L, p.M195V, and p.V198M, do not
involve drastic change in amino acid structure and polar-
ity. They are all present as single heterozygous alleles with-
out the presence of a second pathogenic mutant allele.
Thus, their pathogenicity cannot be determined. Other
changes of the same amino acids have been reported. For
example, p.V63A has been reported as a novel variant,
p.V153I and p.D159N were reported as a polymorphism
[29]. The p.M195V and p.V198M, each occurs in two
patients, without the second mutant allele. Each of the
other variants occurs as heterozygous in one patient.
None of these missense variants were detected in the con-
trol population.
Uncharacterized Novel Silent Variants
Several nucleotide substitutions do not result in amino
acid change. These are p.A49A, p. K61K, p.F146F, and
p.T186T (p.T186T is heterozygous with a single
c.235delC). Although these nucleotide changes do not
alter the encoded amino acids, we cannot exclude the pos-
sibility that they may activate an exonic splice enhancer
and cause aberrant splicing. Alternatively, changes in tri-
plet codon may affect the preference of codon usage or the
stability of the mRNA, which in turn can affect the protein
levels.
Genotypes and Carrier Frequency in the Normal Control 
Population
GJB2 is a small gene but harbors many mutations. Thus,
the carrier frequency of GJB2  mutation in the Chinese
population is not negligible. We sequenced the coding
region of 301 normal control individuals of the Han eth-
nic group. Nine individuals were found to be hetero-
zygous carriers of GJB2 pathogenic mutations; three had
the c.235delC, three had the c.299_c.300delAT, and the
c.512_c.513insAACG, c.35delG, and p.E47X mutation
have been detected in single individuals (see Supplemen-
tal Table 3). Thus, the carrier frequency of GJB2 mutations
in the control population is 3%.
Frequencies of missense variants in patient and control 
populations
The frequencies of common missense variants such as
p.V37I, p.V27I, p.I203T, p.T123N, p.E114G in patients,
control, and other Asian populations were compared (see
Supplemental Table 4 and Table 5). The pathogenic role
of p.V37I has been controversial [24-26,30-33]. It was
found that the p.V37I allele frequency was significantly
higher in the Han patient group (excluding all cases with
two clearly pathogenic mutations) than in the control
group (6.7% and 2.8% respectively,. p = 0.0003), support-
ing a pathogenic role of p.V37I. The allele frequencies of
p.V27I, p.E114G, p.I203T, and p.T123N were higher in
the control group than in the Han patient group (exclud-
ing all cases with two clearly pathogenic mutations), argu-
ing against their pathogenic role (see Supplemental Table
4 and Table 5).
GJB2 mutation spectra among different sub-ethnic groups 
in China
As indicated in Table 2, the frequency of GJB2 mutations
varies from 4% in Guangxi to 30.4% in Jiangsu. These
Amino acid alignment of Connexin26 in different species Figure 2
Amino acid alignment of Connexin26 in different 
species.Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
Page 9 of 12
(page number not for citation purposes)
results suggest that the variation in mutation frequencies
may be due to ethnic diversity in various regions. The total
population of China is 1.3 billion and sub-populations of
Han, Tibetan, Hui, Man, Mon, minorities in Xinjiang, and
minorities in South-western China are 1137.4 million,
5.4 million, 9.8 million, 10.7 million, 5.8 million, 10.8
million, and 57.1 million, respectively (http://
www.cnmuseum.com/intro/renkou_intro.asp, http://
www.xzqh.org/quhua/index.htm). We therefore analyzed
the mutation frequencies in different sub-ethnic groups.
As shown in Supplemental Table 6, Hui has the highest
frequency of overall GJB2 mutations, followed by Han
and minorities in Xinjiang with 20.3, 19.1, and 15.3%
respectively. Tibetan and the minorities in the Southwest
have lower mutation frequencies, 9.4 and 5.0% respec-
tively, similar to the frequencies observed in correspond-
ing regions. The majority of mutations found in this study
were found in the Han patient group (1640 cases) only
except c.35 insG that was in compound heterozygous with
c.235delC found in two Hui patients. The common Cau-
casian mutation, c.35delG was mainly detected in the
minorities of Xinjiang, and accounted for almost half of
the  GJB2  mutant alleles in minorities of Xinjiang (9
c.35delG/19 total mutant alleles). The finding of the
c.35delG mutation in Xinjiang may be due in part to the
close vicinity of Xinjiang to Russia and Eastern European
countries, and possible admixture. The Maan sub-ethnic
group also appears to have diverse GJB2 mutation spec-
trum because mutations other than c.235delC account for
more than one third of the mutant alleles. The three most
common mutations c.235delC, c.299_c.300delAT, and
c.176_c.191del16 account for 100% of GJB2 mutations in
18 Mongolian individuals analyzed. However, the sample
size is too small to be statistically significant.
Discussion
Previous reports have suggested that the prevalence of
GJB2 mutations among different ethnic groups varies. In
our patients, the most common Caucasian mutation,
c.35delG was only found in 10 patients (seven of them
were Uigur from Xinjiang). Instead, the c.235delC
account for 68.9% of all GJB2 mutant alleles in our Chi-
nese study population. These results support that the
c.235delC mutation in connexin 26 gene is the most prev-
alent mutation in most Asian populations, including Han
Chinese [11,24,30,34]. The results from this study indi-
cate that analysis of four common mutations, c.235delC,
c.299_c.300delAT, c.176_c.191del16, and 35delG can
detect 88.0% (650/739) of GJB2 mutations. In 13 regions
of China, by analyzing these four mutations, we were able
to identified at least one mutant allele in all studied
patients with one or two GJB2 mutations (see Table 2 and
Supplemental Table 2). In contrast, mutations in the GJB2
gene account for a variable proportion of the molecular
etiology of NSHI in different regions and sub-ethnic
groups in China. Our results have tremendous impact on
the design of molecular diagnostic and carrier testing of
NSHI families in China. For example, in addition to the
three most common mutations of c.235delC,
c.299_c.300delAT, c.176_c.191del16, for minorities in
Xinjiang, testing of Caucasian c.35delG mutation should
be included. In patients with Maan ethnic background,
sequencing of the GJB2 coding region should be offered,
since the analysis of three common mutations detects
only 71% of GJB2  mutant alleles. In minorities from
Southwest provinces, although the three most common
mutations account for >90% of all GJB2  mutations,
defects in GJB2 gene account for only a small fraction
(5%, Supplemental Table 2 and Table 6) of mutant alleles
in NSHI patients. Thus, in these groups, analysis of other
NSHI related genes should be pursued.
We recently reported that 7.8% of patients with autosomal
recessive nonsyndromic hearing impairment in China were
homozygous for the most common c.235delC mutation in
GJB2 gene and 8.5% of them carried one mutant allele of
the c.235delC mutation [28]. Sequencing of the coding
region of the GJB2 gene reveals that 14.9% of the patients
carry two pathogenic GJB2 mutation and 6.1% carry only
one mutant allele. These results are comparable to other
reported studies [7,11,13,24,29,30,33-35]. The propor-
tions of patients with GJB2 mutations carrying only one
mutant allele vary among different regions, different sub-
ethnic groups, and different countries
[7,11,13,24,29,30,33-35]. The observation that sequence
analysis of GJB2 gene in subjects with autosomal recessive
NSHI results in a high number of patients with only one
GJB2 mutant allele has been puzzling [23]. Our unpub-
lished data showed that no mutation were found in GJB2
Exon1 and its splicing sequence among 851 deaf individu-
als from Central China in this cohort which suggested
extremely low detection rate of GJB2  Exon1 mutation
among Chinese deaf population. For there is higher fre-
quency of single heterozygous GJB2 mutation detected in
the deaf population than in the normal population in this
study, the further more extensive study of sequence change
in GJB2 Exon1 or promoter area and 3'-UTR, fragment dele-
tion neighboring GJB2 ORF region and digenic inheritance
with other genes are already considered in this large Chi-
nese deaf cohort for elucidating complex pathogenesis of
GJB2 gene to hearing impairment. We already added a par-
agraph in discussion. Thus, a digenic hypothesis was pro-
posed and mutations in two other connexin (Cx) genes,
GJB6 for Cx30 and GJB3 for Cx31 were studied [21,22,36].
In families with clear evidence of linkage to the DFNB1
locus, which contains two genes, GJB2 and GJB6 [6,20], a
common 309 kb deletion, involving the coding region
GJB6 gene upstream of GJB2 gene has been identified and
found to account for up to 10% of DFNB1 alleles in Cauca-
sians [22]. We analyzed the deletion in GJB6 gene in 372Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
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patients from Inner Mongolia and central China, and dele-
tions in GJB6 gene were not detected. Similar studies of
GJB6 mutations in Taiwanese prelingual NSHI patients car-
rying one GJB2 mutant allele also did not detect any delete-
rious mutations in GJB6, consistent with our results [30].
Although the spectrum of rare GJB2  mutations varies
among sub-ethnic groups and in different regions of
China, the same most common c.235delC mutation is
shared. This observation is in agreement with the reports
from the studies of other Asian NSHI patients
[10,11,24,30,34]. However, instead of c.299_c.300delAT
being the second most prevalent mutation, p.G45E
accounts for 16% of the Japanese GJB2 mutations, while
p.G4D accounts for 10.6% of Taiwanese GJB2  mutant
alleles [10,30]. The p.G45E mutation was not detected in
our patients. The p.G4D mutation accounts for only 0.3%
of GJB2 mutant alleles in Chinese NSHI patients and was
recently reported in a US study [29,30].
Among the 23 pathogenic mutations, 14 cause truncated
connexin 26 proteins due to nonsense or frame-shift
mutations, 8 are missense mutations, and one is a dele-
tion of one amino acid. These mutations occur along the
coding region. The truncation mutations account for
92.6% of the mutant alleles. Amino acids sequence
homology alignment reveals that all missense mutations
and unclassified variants occur at an evolutionarily con-
served amino acid (Figure 2).
Three missense variants, p.V63L, p.V153A, and p.V198M,
are located in extracelluar domain 1, 2, and transmem-
brane span 4, respectively, of connexin 26 protein. All
these changes have not been reported in the Connexins
and Deafness mutations database at http://davinci.crg.es/
deafness. However, p.V63L has been found in 1 Taiwan-
ese patient [30]. These three variants likely contribute to
the pathogenesis of deafness, because (a) they were
detected only in the patient group and not in 394 Japa-
nese, 864 Taiwanese, 494 Korean and 301 Chinese (in this
study) hearing normal subjects, and (b) they are evolu-
tionarily conserved in xenopus, mouse, rat, sheep, oran-
gutan, and human (Figure. 2). These variants were found
in a heterozygous state in 4 unrelated patients who carried
only one mutant allele.
The pathogenicity of p.V37I is controversial. In a recent
multicenter study, the p.V37I mutation was found to be
associated with mild to moderate hearing impairment
(median 25–40 dB) [37]. Our study revealed that p.V37I
with an allele frequency of 6.7% (185/2744) in the Han
patient group (excluding all cases with two clearly patho-
genic mutations) is significantly higher compared with
that (2.8%;17/602) found in the control population (p =
0.0003, see Supplemental Table 4 and Table 5), support-
ing Wu's opinion to reassignment of p. V37I from an
allele variant to a pathogenic mutation [38].
The p.T123N is an unclassified variant. It was counted as
a mutation in Japanese group but a polymorphism in a
Taiwanese study [10,30]. We found a higher p.T123N
allele frequency in the control group than in the patient
group, suggesting that it may be neutral variant. However,
its clinical implication is not clear at this time.
The results of this study provide a great potential benefit
for the clinical application of genetic testing for deafness.
Based upon our preliminary data of molecular epidemiol-
ogy of hearing impairment in China [28,39-41], Li has
combined allele-specific PCR and universal array
(ASPUA) methodologies for the detection of mutations
causing hereditary hearing loss. It was employed for mul-
tiplex detection of 11 mutations in GJB2, GJB3, SLC26A4
and mitochondrial DNA causing hereditary hearing loss
[42]. Although this simple screening chip only include
probes and primers for the c.35delG, c.176_c.191del16,
c.235delC, c.299_c.300delAT mutations of GJB2 gene, it
can detect 88.0% (650/739) of GJB2 mutations among
these 2063 deaf individuals, meanwhile, up to 88.9%
(384/432) of 432 patients confirmed to carry at least one
GJB2 mutation by sequencing in this study will be picked
up by this fast screen method. The new methods for mul-
tiple mutation detection including ASPUA with capacity
to test more gene loci have been under developed in our
center, the data of this study will be crucial for the muta-
tion selection in any new technology development for
GJB2 gene testing in Chinese population.
In summary, this study revealed a unique GJB2 mutation
spectrum in Chinese patients with nonsyndromic hearing
impairment. The c.235delC mutation is the most frequent
mutation in Chinese patients. Testing of four common
mutations, c.235delC, c.299_c.300delAT,
c.176_c.191del16, and c.35delG can detect 88.0% of the
GJB2 mutant alleles. However, in some regions or sub-
ethnic groups, the GJB2  mutations only account for a
small fraction of the NSHI mutant alleles. In these
regions, analysis of NSHI related genes is necessary. The
molecular defects of more than 80% of the mutant alleles
for NSHI in China remain to be identified.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PD, FY and BH carried out the molecular genetic studies,
participated in the sequence alignment and drafted the
manuscript. GW, QL, YY, XL, KY, JH, JH, YH, YW, QY, YY,
HL, LL, WD, XZ, YY, JC, NH, XX, JZ, LT, RS, YL, SS, RZ, HW
and YM carried out epidemiological survey.Journal of Translational Medicine 2009, 7:26 http://www.translational-medicine.com/content/7/1/26
Page 11 of 12
(page number not for citation purposes)
DK and XZ participated in the sequence alignment. SZHY
and DH participated in the design of the study and per-
formed the statistical analysis. PD, DH, XL and BW con-
ceived of the study, and participated in its design and
coordination and helped to draft the manuscript. L-JW
reviewed and interpreted the results, drafted and revised
the manuscript.
Acknowledgements
The authors would like to thank Dr. Dennis Johnson and Dr. Raye L. Alford 
for their valuable suggestions. This work was supported by the Chinese 
National Nature Science Foundation Research Grant 30728030,30872862, 
and Chinese Capital Medical Development Scientific Funding 2005-1032 to 
Dongyi Han.
The authors also would like to thank the Fuyang School for the Deaf and 
Dumb (Anhui province), Beijing No.3 School for the Deaf (Beijing), Pinggu 
Special Education School (Beijing), Beijing Children's Hospital(Beijing), 
Fuzhou Special Education School (Fujian province), Lanzhou Convalescent 
Center for Deaf Children (Gansu province), Gansu Convalescent Ccenter 
for Deaf Children (Gansu province), Foshan School for the Deaf and Dumb 
(Guangdong province), Liuzhou School for the Bblind Deaf and Dumb 
(Guangxi province), Guiyang School for the Blind, Deaf and Dumb (Guizhou 
Province), Zhuozhou and Gaobeidian School for the Ddeaf and Dumb 
(Hebei province), Mudanjiang Special Education School (Heilongjiang prov-
ince), Anyang Special Education School (Henan province), Wuhan Yimeng 
Convalescent Center for Deaf Children (Hubei province), Chifeng Special 
Education School (Inner Mongolia), Nantong School for the Deaf and Dumb 
(Jiangsu province), Haian School for the Deaf and Dumb (Jiangsu province), 
Haimen School for the Deaf and Dumb (Jiangsu province), Rugao School for 
the Deaf and Dumb (Jiangsu province), Tongzhou School for the Deaf and 
Dumb (Jiangsu province), Jilin Special Education School (Jilin province), Yin-
chuan School for the Blind, Deaf and Dumb (Ningxia Province), Xining Spe-
cial Education School (Qinghai province), Changan School for the Deaf and 
Dumb (Shaanxi province), Affiliated Pediatric Medical Center of Shanghai 
Jiao Tong University (Shanghai), Yuncheng School for the Deaf and Dumb 
(Shanxi province), Yuncheng Disabled Person's Federation (Shanxi prov-
ince), Yuncheng Convalescent Center for Deaf Children (Shanxi province), 
Chengdu Special Education School (Sichuan province), Urumchi School for 
the Deaf and Dumb (Xinjiang province), Korla School for the Deaf and 
Dumb (Xinjiang province), Kunming Huaxia Secondary School (Yunnan 
province), Kunming Convalescent Center for Deaf Children (Yunnan prov-
ince), Lincang Special Education School (Yunnan province), Kunming Con-
valescent Center for Deaf Children (Yunnan province) and Lhasa Special 
Education School (Tibet municipality area) for their fundamental support 
and contributions to this work.
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